AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30114726 — intervention group
Group type: EXPERIMENTAL
Intervention: dmft
Number of subjects: 0
Study 30114726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of untreated decay
Number of subjects: 0
Study 30114726 — intervention group
Group type: COMPARATOR
Intervention: TOCE compared with controls
Number of subjects: 0
Study 27506971 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtX‐A) injection (200 IU) in the quadriceps muscles
Number of subjects: 44
Study 27506971 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline injection)
Number of subjects: 44
Study 25002161 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 830
Study 25002161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 830
Study 25002161 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 830
Study 25002161 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with PAD
Number of subjects: 830
Study 23083041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 40
Study 23083041 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 19240664 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous coated motion (PCM) artificial cervical disc in primary patients (no previous fusion)
Number of subjects: 152
Study 19240664 — intervention group
Group type: COMPARATOR
Intervention: Porous coated motion (PCM) artificial cervical disc in adjacent level fusion patients
Number of subjects: 152
Study 19240664 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 152
Study 17480179 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 14742982 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements with morning dose of MMF (n=14)
Number of subjects: 40
Study 14742982 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements given 4 hr after MMF at midday (n=13)
Number of subjects: 40
Study 14742982 — intervention group
Group type: COMPARATOR
Intervention: No iron supplements (n=13)
Number of subjects: 40
Study 11577951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan in surgical group
Number of subjects: 15
Study 11577951 — intervention group
Group type: COMPARATOR
Intervention: Control group in surgical treatment
Number of subjects: 15
Study 11577951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan in non-surgical group
Number of subjects: 15
Study 11577951 — intervention group
Group type: COMPARATOR
Intervention: Control group in non-surgical treatment
Number of subjects: 15
Study 11577951 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical and non-surgical groups
Number of subjects: 15
Study 11577951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan
Number of subjects: 15
Study 9628449 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg IV bolus followed by SC injections of 1.0 mg/kg every 12 hours)
Number of subjects: 0
Study 9628449 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (70 U/kg bolus followed by infusion of 15 U/kg per hour)
Number of subjects: 0
Study 9628449 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (fixed-dose SC enoxaparin 60 mg every 12 hours for patients ≤65 kg, 40 mg every 12 hours for patients <65 kg)
Number of subjects: 0
Study 9628449 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 8051381 — intervention group
Group type: EXPERIMENTAL
Intervention: malotilate 1500 mg/day
Number of subjects: 407
Study 8051381 — intervention group
Group type: EXPERIMENTAL
Intervention: malotilate 750 mg/day
Number of subjects: 407
Study 8051381 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 407
Study 2723511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen needle (SLN)
Number of subjects: 44
Study 2723511 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen needle (DLN)
Number of subjects: 44
Study 20034170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (60-120 mg daily)
Number of subjects: 26
Study 20034170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31997704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal administration of vasopressin (AVP)
Number of subjects: 25
Study 31997704 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's birth
Number of subjects: 25
Study 31958773 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma S-Klotho concentrations in middle-aged adults
Number of subjects: 214
Study 31958773 — intervention group
Group type: COMPARATOR
Intervention: Higher plasma S-Klotho concentrations in young adults
Number of subjects: 214
Study 31818843 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous resection of the primary pancreatic cancer lesion and liver oligometastases
Number of subjects: 300
Study 31818843 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 300
Study 27696786 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 606
Study 27696786 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 606
Study 27696786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 25437533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 742
Study 25437533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 24006882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer with cause specified (HPV, a STI)
Number of subjects: 478
Study 24006882 — intervention group
Group type: COMPARATOR
Intervention: Cervical cancer with cause unspecified
Number of subjects: 478
Study 21288628 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20 μg/drsp 3mg COC (n=451)
Number of subjects: 893
Study 21288628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=442)
Number of subjects: 893
Study 19473905 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation programme (Gp A)
Number of subjects: 107
Study 19473905 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy (Gp B)
Number of subjects: 107
Study 17093248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (1.5 mg/kg daily for 5 days)
Number of subjects: 278
Study 17093248 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab (20 mg on days 0 and 4)
Number of subjects: 278
Study 17093248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Number of subjects: 278
Study 17093248 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab
Number of subjects: 278
Study 15462699 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily
Number of subjects: 138
Study 15462699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 11172151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy with iridium-192
Number of subjects: 252
Study 11172151 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonradioactive ribbon)
Number of subjects: 252
Study 9506734 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200‐800 mg daily)
Number of subjects: 18
Study 9506734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7710471 — intervention group
Group type: EXPERIMENTAL
Intervention: Marlex mesh
Number of subjects: 102
Study 7710471 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 102
Study 2454038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladosporium immunotherapy
Number of subjects: 22
Study 2454038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1073187 — intervention group
Group type: EXPERIMENTAL
Intervention: alexidine dihydrochloride oral rinse
Number of subjects: 167
Study 1073187 — intervention group
Group type: COMPARATOR
Intervention: placebo oral rinse
Number of subjects: 167
Study 30466306 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified semiblind fasciotomy of the anterior compartment
Number of subjects: 64
Study 29343693 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (REAL)
Number of subjects: 56
Study 29343693 — intervention group
Group type: COMPARATOR
Intervention: Phantom acupuncture (PHNT)
Number of subjects: 56
Study 27638148 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 60
Study 27638148 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 27638148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27638148 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including LLLT, control, and placebo)
Number of subjects: 60
Study 24486163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-at-home treatment
Number of subjects: 139
Study 24486163 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 139
Study 22998716 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically indicated replacement
Number of subjects: 3283
Study 22998716 — intervention group
Group type: COMPARATOR
Intervention: Routine replacement
Number of subjects: 3283
Study 19936767 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated chemotherapy
Number of subjects: 958
Study 19936767 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 958
Study 17336373 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 100
Study 17336373 — intervention group
Group type: COMPARATOR
Intervention: No educational video intervention (Control)
Number of subjects: 100
Study 16336029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol (2mg once-daily applied as a patch)
Number of subjects: 92
Study 16336029 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 microg per inhalation, twice a day)
Number of subjects: 92
Study 11882468 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk consumption (mean 50 g/day, 95% CI 44-55 g/day)
Number of subjects: 649
Study 11882468 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk consumption (varied by region: rural 9 g/day, suburban 36 g/day, urban 83 g/day)
Number of subjects: 649
Study 11882468 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk consumption as a dietary factor
Number of subjects: 649
Study 10612357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB; Gabitril) at doses of 32 mg/day and 56 mg/day
Number of subjects: 0
Study 10612357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB; Gabitril) administered twice, three times, and four times daily
Number of subjects: 0
Study 10612357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB; Gabitril)
Number of subjects: 0
Study 8574231 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 41
Study 8574231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2278377 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous morphine application (0.5-1.0 microgram/kg per min)
Number of subjects: 12
Study 2278377 — intervention group
Group type: COMPARATOR
Intervention: Bolus morphine injections (0.05 mg/kg)
Number of subjects: 12
Study 6118666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular yttrium-90 (5 mCi) plus steroid (triamcinolone hexacetonide, 20 mg)
Number of subjects: 15
Study 6118666 — intervention group
Group type: COMPARATOR
Intervention: Saline plus steroid (control)
Number of subjects: 15
Study 31478436 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-month high-intensity interval neuromuscular training programme (DoIT)
Number of subjects: 49
Study 30291016 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality weight gain prevention intervention (10 weekly peer-support sessions)
Number of subjects: 39
Study 30291016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 28272228 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR)
Number of subjects: 50
Study 28272228 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/remifentanil (SR)
Number of subjects: 50
Study 25041234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (500 mg twice a day for 8 weeks)
Number of subjects: 58
Study 25041234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24713310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol sustained-release (SR) [average daily dose 433 (31) mg]
Number of subjects: 24
Study 24713310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22797188 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg of risedronate weekly
Number of subjects: 42
Study 22797188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20680681 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus tamoxifen
Number of subjects: 191
Study 20680681 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin alone
Number of subjects: 191
Study 17414245 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 30
Study 17414245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17414245 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (post hoc analysis)
Number of subjects: 30
Study 15969759 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified beverage (1,125 mg Ca++/d)
Number of subjects: 37
Study 15969759 — intervention group
Group type: COMPARATOR
Intervention: Control group (free-living)
Number of subjects: 37
Study 12171747 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence from randomised controlled trials (RCTs) and systematic reviews of RCTs
Number of subjects: 124
Study 12171747 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised quantitative studies and qualitative studies
Number of subjects: 124
Study 12171747 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluations
Number of subjects: 124
Study 9718289 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (500 mg)
Number of subjects: 20
Study 9718289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7663789 — intervention group
Group type: EXPERIMENTAL
Intervention: Four measurements taken 8 hours apart
Number of subjects: 20
Study 7663789 — intervention group
Group type: EXPERIMENTAL
Intervention: Two measurements (one upon arising and one 12 hours later or before retiring)
Number of subjects: 20
Study 7663789 — intervention group
Group type: COMPARATOR
Intervention: Full 24-hour lung function profile (thirteen 2-hourly measurements)
Number of subjects: 20
Study 2758900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum saline amnio-infusion
Number of subjects: 60
Study 2758900 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amnio-infusion)
Number of subjects: 60
Study 435349 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium infusion at 0.25 mg s‐1 to 20 mg s‐1
Number of subjects: 42
Study 435349 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg i.v. bolus dose of Suxamethonium
Number of subjects: 42
Study 30896030 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction (mbsr)
Number of subjects: 148
Study 28752575 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL (BBL™ BroadBand Light; Sciton, Palo Alto, CA)
Number of subjects: 15
Study 28752575 — intervention group
Group type: COMPARATOR
Intervention: PDL (Cynergy™; Cynosure, Westford, MA)
Number of subjects: 15
Study 25618476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 48
Study 25618476 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy
Number of subjects: 48
Study 24245598 — intervention group
Group type: EXPERIMENTAL
Intervention: The Girlfriends Project (TGP) intervention
Number of subjects: 149
Study 24245598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 21714697 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended letrozole regimen (5 mg/day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days) combined with HPuFSH-GnRHant protocol
Number of subjects: 136
Study 21714697 — intervention group
Group type: COMPARATOR
Intervention: Short letrozole regimen (2.5 mg/day from cycle day 3-7) combined with HPuFSH-GnRHant protocol
Number of subjects: 136
Study 21714697 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended letrozole regimen
Number of subjects: 136
Study 21714697 — intervention group
Group type: COMPARATOR
Intervention: Short letrozole regimen
Number of subjects: 136
Study 19187616 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 microg/kg
Number of subjects: 102
Study 19187616 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 microg/kg
Number of subjects: 102
Study 19011013 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal incision
Number of subjects: 110
Study 19011013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal incision
Number of subjects: 110
Study 19011013 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior incision
Number of subjects: 110
Study 19011013 — intervention group
Group type: COMPARATOR
Intervention: All incision types
Number of subjects: 110
Study 16306073 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI)
Number of subjects: 0
Study 16306073 — intervention group
Group type: COMPARATOR
Intervention: Comparison districts (without IMCI)
Number of subjects: 0
Study 12201832 — intervention group
Group type: EXPERIMENTAL
Intervention: 10, 15 or 20 mg of pegvisomant
Number of subjects: 27
Study 12201832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9667343 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE-Q kit with modified technique
Number of subjects: 20
Study 9667343 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE-S kit with modified technique
Number of subjects: 20
Study 9667343 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE-Q kit with upward orientation of epidural needle bevel
Number of subjects: 20
Study 9667343 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE-S kit with upward orientation of epidural needle bevel
Number of subjects: 20
Study 7642860 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 270
Study 7642860 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up costs after primary angioplasty
Number of subjects: 270
Study 7642860 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat coronary angiography
Number of subjects: 270
Study 7642860 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat angioplasty
Number of subjects: 270
Study 7642860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 270
Study 7642860 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of higher baseline hospital costs
Number of subjects: 270
Study 2760255 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlessness during parabolic flight
Number of subjects: 0
Study 2760255 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlessness in semi-supine posture
Number of subjects: 0
Study 145212 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanol acetamidobenzoate
Number of subjects: 9
Study 145212 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 9
Study 145212 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine mesylate
Number of subjects: 9
Study 145212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11793023 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone, 8 mg/day (n = 15)
Number of subjects: 29
Study 30767166 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol
Number of subjects: 190
Study 30767166 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl
Number of subjects: 190
Study 28984634 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth knowledge base in addition to standard care
Number of subjects: 208
Study 28984634 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 208
Study 27636505 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (SA)
Number of subjects: 442
Study 27636505 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 442
Study 27636505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 442
Study 24316262 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 1125 mg twice daily
Number of subjects: 740
Study 24316262 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir 750 mg every 8 hours
Number of subjects: 740
Study 24316262 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (both regimens)
Number of subjects: 740
Study 22699675 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol wipes
Number of subjects: 44
Study 22699675 — intervention group
Group type: COMPARATOR
Intervention: Placebo wipes
Number of subjects: 44
Study 20194386 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide immediately after bleaching
Number of subjects: 20
Study 20194386 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide seven days after bleaching
Number of subjects: 20
Study 20194386 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide fourteen days after bleaching
Number of subjects: 20
Study 20194386 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide twenty-one days after bleaching
Number of subjects: 20
Study 20194386 — intervention group
Group type: COMPARATOR
Intervention: No bleaching treatment (controls)
Number of subjects: 20
Study 17394960 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 120 mg once daily for 7 days
Number of subjects: 19
Study 17394960 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (24 mg/min) during intra-arterial coinfusion after IS‐5‐MN therapy
Number of subjects: 19
Study 17394960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19